This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?

This company hasn't made its debut on the weight-loss market yet, but it may. First things first. Appreciate that Roche's weight-loss pill program is currently in phase 1 clinical trials. The first two parts of the three-part trial are done, and the third hasn't started yet. It will need plenty more research and development (R&D) work before it's ready to submit to regulators for approval, assuming it ever is. Any early results may or may not be substantiated by subsequent clinical investigations. Another m ...